The company unveiled TxGemma, a collection of Gemma-based open models aimed at improving the efficiency of AI-powered drug discovery, during its recent Check Up event.
A study published in medRxiv reveals that inference techniques including chain-of-thought and search augmented generation can reduce AI hallucination rates.
Dr. Ricky Bloomfield, Oura's first CMO, spoke with MobiHealthNews about his plans for the company and his vision to personalize Oura's offerings using generative AI.